TY - JOUR
T1 - Epidemiology, clinical evolution and outcomes of tracheobronchitis and pneumonia associated with mechanical ventilation in intensive care units of Latin America (LATINAVE study)
AU - Varón-Vega, Fabio Andrés
AU - Hernández-Parra, Ángela
AU - Molina, Francisco
AU - Poveda, Claudia Marcela
AU - Meza, Rafael Arturo
AU - Castro, Heidi
AU - Vergara, José
AU - Mayorga, Manuel
AU - Pérez, Mario
AU - Cepeda, Ernesto
AU - Vega-Barrientos, Ricardo
AU - Pareja, Massimo
AU - Urbina, Zulma
AU - Mercado, José
AU - Martínez-Pino, José
AU - Sánchez, Miguel
AU - Camargo, Francisco
AU - Alí-Munivea, Abraham
PY - 2017
Y1 - 2017
N2 - Introduction: The infections associated with mechanical ventilation are a major cause of morbidity and mortality in critically ill patients. Limited studies report increased mortality and intensive care units (ICU) stays, requirements for mechanical ventilation and higher costs in ventilator-associated tracheobronchitis (TAV) in comparison to patients with ventilator-associated pneumonia (NAV). These studies do not describe the clinical and epidemiological behavior in the same population as independent entities, so it is necessary to describe the epidemiology of patients with TAV and NAV. Methods: Multicenter cross-sectional study of adult patients who developed TAV and/or NAV during their stay in the ICU in 2013 to 2014. A descriptive analysis was performed on each of the variables. For qualitative variables we assessed differences between groups using the Chi-squared test; for continuous variables, we used Student's t test or the Mann Whitney U test. Results: A total of 147 patients from 6 countries in Latin America were included; 63[%] with NAV and 37[%] with TAV. The average age was 55 years; 57[%] male. The most frequent comorbidity was cardiovascular (44[%]) and neurological (30[%]), the latter was more frequent in those with TAV (41.5 vs. 23[%], P = .02). No differences were found in APACHE II on entry, but the difference appears in the SOFA index (8 vs. 5, P = .02). There were no differences in microbiological isolation, or bacterial resistance patterns between the 2 entities. A greater number of cardio-vascular complications and ARDS were observed in patients with NAV. The ICU stay, days on mechanical ventilation and mortality were not different between the 2 groups. Conclusions: The TAV prevalence was higher than heretofore described in the literature. No significant differences were found in the microbiological isolation, bacterial resistance and antibiotic therapy used in the 2 groups, which might suggest that therapeutic approach be similar to that recommended for NAV. No differences were observed in clinical outcomes such as hospital stay, duration of mechanical ventilation and mortality, although NAV was associated with a greater proportion of medical complications.
AB - Introduction: The infections associated with mechanical ventilation are a major cause of morbidity and mortality in critically ill patients. Limited studies report increased mortality and intensive care units (ICU) stays, requirements for mechanical ventilation and higher costs in ventilator-associated tracheobronchitis (TAV) in comparison to patients with ventilator-associated pneumonia (NAV). These studies do not describe the clinical and epidemiological behavior in the same population as independent entities, so it is necessary to describe the epidemiology of patients with TAV and NAV. Methods: Multicenter cross-sectional study of adult patients who developed TAV and/or NAV during their stay in the ICU in 2013 to 2014. A descriptive analysis was performed on each of the variables. For qualitative variables we assessed differences between groups using the Chi-squared test; for continuous variables, we used Student's t test or the Mann Whitney U test. Results: A total of 147 patients from 6 countries in Latin America were included; 63[%] with NAV and 37[%] with TAV. The average age was 55 years; 57[%] male. The most frequent comorbidity was cardiovascular (44[%]) and neurological (30[%]), the latter was more frequent in those with TAV (41.5 vs. 23[%], P = .02). No differences were found in APACHE II on entry, but the difference appears in the SOFA index (8 vs. 5, P = .02). There were no differences in microbiological isolation, or bacterial resistance patterns between the 2 entities. A greater number of cardio-vascular complications and ARDS were observed in patients with NAV. The ICU stay, days on mechanical ventilation and mortality were not different between the 2 groups. Conclusions: The TAV prevalence was higher than heretofore described in the literature. No significant differences were found in the microbiological isolation, bacterial resistance and antibiotic therapy used in the 2 groups, which might suggest that therapeutic approach be similar to that recommended for NAV. No differences were observed in clinical outcomes such as hospital stay, duration of mechanical ventilation and mortality, although NAV was associated with a greater proportion of medical complications.
UR - http://www.scopus.com/inward/record.url?scp=85020164053&partnerID=8YFLogxK
U2 - 10.22354/in.v21i2.650
DO - 10.22354/in.v21i2.650
M3 - Artículo en revista científica indexada
AN - SCOPUS:85020164053
SN - 0123-9392
VL - 21
SP - 74
EP - 80
JO - Infectio
JF - Infectio
IS - 2
ER -